Published in J Invest Dermatol on October 29, 2009
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol (2011) 1.63
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol (2011) 1.30
Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases. Nat Rev Cancer (2012) 0.99
Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. Immunogenetics (2010) 0.95
Familial occurrence of systemic mast cell activation disease. PLoS One (2013) 0.95
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia (2015) 0.95
SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. Haematologica (2014) 0.93
Current concepts on diagnosis and treatment of mastocytosis. Transl Med UniSa (2014) 0.91
Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics. Immunology (2012) 0.89
Mastocytosis in children and adults: clinical disease heterogeneity. Arch Med Sci (2012) 0.89
KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells. Exp Hematol (2013) 0.89
A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). Mod Pathol (2013) 0.88
Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. Immunol Allergy Clin North Am (2014) 0.86
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol (2013) 0.86
Evidence for contribution of epigenetic mechanisms in the pathogenesis of systemic mast cell activation disease. Immunogenetics (2014) 0.85
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Res (2017) 0.83
The serum tryptase test: an emerging robust biomarker in clinical hematology. Expert Rev Hematol (2014) 0.83
Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers. Proc Natl Acad Sci U S A (2014) 0.83
Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. Leuk Res (2014) 0.83
Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood (2016) 0.82
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica (2014) 0.82
Systemic mastocytosis - a diagnostic challenge. Rev Bras Hematol Hemoter (2014) 0.82
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PLoS One (2011) 0.81
Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Curr Allergy Asthma Rep (2013) 0.80
Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res (2013) 0.80
Skin tumors in childhood. Dtsch Arztebl Int (2011) 0.79
Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity. PLoS Comput Biol (2014) 0.79
KIT masters mast cells in kids, too. J Invest Dermatol (2010) 0.78
Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. Ann Hematol (2014) 0.78
Mastocytosis in children is associated with mutations in c-KIT. J Invest Dermatol (2010) 0.78
Pediatric Mastocytosis: A Review of the Literature. Pediatr Allergy Immunol Pulmonol (2013) 0.78
Genome-Wide Association Study of Golden Retrievers Identifies Germ-Line Risk Factors Predisposing to Mast Cell Tumours. PLoS Genet (2015) 0.77
Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature. Int J Clin Exp Pathol (2014) 0.77
Targeted Treatment Options in Mastocytosis. Front Med (Lausanne) (2017) 0.76
Kit transduced signals counteract erythroid maturation by MAPK-dependent modulation of erythropoietin signaling and apoptosis induction in mouse fetal liver. Cell Death Differ (2014) 0.76
Syndromic gastrointestinal stromal tumors. Hered Cancer Clin Pract (2016) 0.76
Characterization of various types of mast cells derived from model mice of familial gastrointestinal stromal tumors with KIT-Asp818Tyr mutation. Int J Clin Exp Pathol (2015) 0.76
Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders. Clin Exp Allergy (2014) 0.75
Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder. Oncotarget (2015) 0.75
The spleen microenvironment influences disease transformation in a mouse model of KIT(D816V)-dependent myeloproliferative neoplasm. Sci Rep (2017) 0.75
Mastocytosis 2016: Updated WHO Classification and Novel Emerging Treatment Concepts. Blood (2016) 0.75
A child with mastocytosis and lymphomatoid papulosis. Clin Case Rep (2016) 0.75
Mastocytosis among elderly patients: A multicenter retrospective French study on 53 patients. Medicine (Baltimore) (2016) 0.75
A Case of Intestinal Mastocytosis Misdiagnosed as Crohn's Disease. Case Rep Gastroenterol (2015) 0.75
A point mutation in the extracellular domain of KIT promotes tumorigenesis of mast cells via ligand-independent auto-dimerization. Sci Rep (2015) 0.75
Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. J Allergy Clin Immunol (2015) 0.75
How Intrinsic Molecular Dynamics Control Intramolecular Communication in Signal Transducers and Activators of Transcription Factor STAT5. PLoS One (2015) 0.75
Expression and mutation of c-Kit in intracranial germ cell tumors: A single-centre retrospective study of 30 cases in China. Oncol Lett (2016) 0.75
Mast cell sarcoma: new cases and literature review. Oncotarget (2016) 0.75
Mastocytosis in Children. Curr Allergy Asthma Rep (2017) 0.75
Anesthetic considerations in pediatric mastocytosis: a review. J Anesth (2013) 0.75
Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer. Front Med (Lausanne) (2017) 0.75
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Magnetic domain-wall racetrack memory. Science (2008) 8.24
N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol (2011) 5.96
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2007) 5.84
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med (2002) 5.58
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA (2011) 4.84
Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med (2004) 4.47
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst (2005) 4.01
Extra-embryonic function of Rb is essential for embryonic development and viability. Nature (2003) 3.92
Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med (2008) 3.85
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med (2011) 3.63
Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol (2007) 3.54
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther (2003) 3.34
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A (2002) 3.11
Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis (2010) 3.07
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med (2009) 3.07
Chiral spin torque at magnetic domain walls. Nat Nanotechnol (2013) 2.98
Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med (2011) 2.93
Telemedical wound care using a new generation of mobile telephones: a feasibility study. Arch Dermatol (2005) 2.91
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2008) 2.91
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med (2007) 2.85
Dermoscopic examination of nail pigmentation. Arch Dermatol (2002) 2.83
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol (2004) 2.81
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol (2012) 2.78
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science (2010) 2.75
Is breast cancer survival improving? Cancer (2004) 2.73
Current-controlled magnetic domain-wall nanowire shift register. Science (2008) 2.68
Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol (2008) 2.67
Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica (2005) 2.66
Platelet formation is the consequence of caspase activation within megakaryocytes. Blood (2002) 2.62
Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med (2012) 2.55
NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells. Blood (2008) 2.54
Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BMC Genomics (2008) 2.51
A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol (2002) 2.47
Pax6 is a human neuroectoderm cell fate determinant. Cell Stem Cell (2010) 2.46
Single-spike detection in vitro and in vivo with a genetic Ca2+ sensor. Nat Methods (2008) 2.44
WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood (2004) 2.41
Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology (2008) 2.39
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood (2007) 2.36
Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis (2009) 2.33
Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr (2007) 2.32
Clinical study of 40 cases of incontinentia pigmenti. Arch Dermatol (2003) 2.29
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res (2004) 2.28
Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol (2010) 2.27
NF-1Score: a prediction score for internal neurofibromas in neurofibromatosis-1. J Invest Dermatol (2010) 2.25
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet (2002) 2.23
Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis (2002) 2.20
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet (2012) 2.17
Skin markers of occult spinal dysraphism in children: a review of 54 cases. Arch Dermatol (2004) 2.16
Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J (2010) 2.13
C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2011) 2.12
Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS (2004) 2.11
Dependence of current and field driven depinning of domain walls on their structure and chirality in permalloy nanowires. Phys Rev Lett (2006) 2.11
Sturge-Weber syndrome in patients with facial port-wine stain. Pediatr Dermatol (2011) 2.06
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood (2006) 2.06
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica (2007) 2.03
Referent d-dimer enzyme-linked immunosorbent assay testing is of limited value in the exclusion of thromboembolic disease: result of a practical study in an ED. Am J Emerg Med (2006) 2.02
Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease. Gastroenterology (2006) 2.01
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
Ivory vertebra and systemic mastocytosis. Joint Bone Spine (2012) 1.97
PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases. Nat Med (2013) 1.96
Molecular identification of zygomycetes from culture and experimentally infected tissues. J Clin Microbiol (2006) 1.96
DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med (2004) 1.96
Cutaneous hematologic disorders in children. Pediatr Blood Cancer (2011) 1.95
Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. Hum Mol Genet (2004) 1.94
Identification of mutations in a new gene encoding a FERM family protein with a pleckstrin homology domain in Kindler syndrome. Hum Mol Genet (2003) 1.94
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J Am Chem Soc (2013) 1.90
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res (2008) 1.87
Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis (2012) 1.84
A cytochrome C oxidase model catalyzes oxygen to water reduction under rate-limiting electron flux. Science (2007) 1.84
Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood (2002) 1.84
Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol (2006) 1.83
[Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004)]. Bull Cancer (2004) 1.80
DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol (2006) 1.80
Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. J Natl Cancer Inst (2006) 1.80